We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Tacere Enters Collaboration and License Agreement with Pfizer to Develop and Commercialize RNAi Hepatitis C Drug

News   Jan 10, 2008

 
Tacere Enters Collaboration and License Agreement with Pfizer to Develop and Commercialize RNAi Hepatitis C Drug
 
 
 

RELATED ARTICLES

Embryonic Stem Cells Commit to Their Fate Earlier Than First Thought

News

This study challenges the longstanding assumption that embryonic stem cells remain quite plastic and malleable during the earliest stages of cell commitment.

READ MORE

Chemists’ Success in Synthesis Drives Development of Anti-cancer Agent

News

Researchers have now synthesized sufficient quantities of E7130, a drug candidate from the halichondrin class, to enable for the first time rigorous studies of its biological activity, pharmacological properties, and efficacy.

READ MORE

Discovery Could Help Treat People With Cardiovascular Disease

News

Researchers have found a link between a peptide called apelin and a reduction of abdominal aortic aneurysms that was shown to dramatically reduce mortality in mice. They are using this knowledge to develop a new medical therapy to treat cardiovascular disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE